Allergy Immunotherapy

Policy No: 100
Date of Origin: 07/01/2020
Section: Administrative
Last Reviewed: 10/01/2023
Last Revised: 06/01/2023
Approved: 10/12/2023
Effective: 11/01/2023

This policy applies only to physicians and other qualified healthcare professionals.


Allergen immunotherapy ‒ the repeated administration of specific allergens to patient for the purpose of providing protection against inflammatory reactions and associated allergy symptoms with natural exposure to these allergens.

Dose ‒ a single dose is the amount of antigen or antigens administered in a single injection from a multiple dose vial or drawn from a treatment board in one syringe.

Current Procedural Terminology (CPT®) 95165 ‒ Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; single or multiple dose antigens (specify the number of doses).

Policy Statement

The units billed for code 95165 should reflect the actual number of doses the provider plans to administer as the patient’s course of treatment when the antigen is initially prepared. Depending on the patient treatment plan, preparation of the antigen may be billed more than once per year but limited to once per course of treatment. Regardless of the number of treatment plan(s) in any given year, the units billed are still subject to the unit maximum below per 365 days. Units should be billed on the preparation date and not split over subsequent days. If the patient’s doses are adjusted and the antigen provided is more or fewer doses than originally anticipated, there should be no change in the number of doses for which the provider already anticipated billing.

Effective with dates of service on or after November 1, 2021, the following limits will be applied to code 95165:

  • 150 units per 365 days/per member maximum

Individuals must be re-evaluated every 6 to 12 months while receiving allergy immunotherapy for all the following:

  • To determine efficacy; and
  • To determine whether adjustments in the dosing schedule or allergen content are necessary; and
  • To ensure compliance; and
  • To monitor for the two types of adverse reactions: local (i.e., redness and swelling at the injection site) and systemic (i.e., sneezing, nasal congestion, or hives).

The length of time that a patient would have ongoing immunotherapy should be individualized based on the patient’s clinical response, disease severity and immunotherapy reaction history. The duration of the course of treatment is determined upon each patient. Records must be submitted if requested to verify this.

Immunotherapy includes professional services necessary for the preparation and provision of the allergen immunotherapy.

If additional separate and distinct services are rendered at the same time as the preparation of the allergen immunotherapy, then an appropriate evaluation and management (E&M) office visit code with modifier 25 may be submitted if documentation supports that separate and distinct services were rendered.


American Academy of Allergy, Asthma and Immunology. Allergen Immunotherapy: A practice parameter third update, Jan. 2011, Editors: Lind Cox MD, Harold Nelson MD and Rachel Lockey MD

Centers for Medicare & Medicaid Services (CMS), Medicare Claims Processing Manual, Chapter 12, Section 200-Allergy Testing and immunotherapy

Centers for Medicare & Medicaid Services (CMS), Medicare Benefits Policy Manual, Chapter 15, Section 50.4.4-Payment for Antigens and Immunotherapy


Your use of this Reimbursement Policy constitutes your agreement to be bound by and comply with the terms and conditions of the Reimbursement Policy Disclaimer.